Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.
Syngenta, Jealott's Hill International Research Centre, Bracknell, Berkshire RG42 6EY, United Kingdom.
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17992-18001. doi: 10.1073/pnas.2003056117. Epub 2020 Jul 15.
Dengue virus (DENV) was designated as a top 10 public health threat by the World Health Organization in 2019. No clinically approved anti-DENV drug is currently available. Here we report the high-resolution cocrystal structure (1.5 Å) of the DENV-2 capsid protein in complex with an inhibitor that potently suppresses DENV-2 but not other DENV serotypes. The inhibitor induces a "kissing" interaction between two capsid dimers. The inhibitor-bound capsid tetramers are assembled inside virions, resulting in defective uncoating of nucleocapsid when infecting new cells. Resistant DENV-2 emerges through one mutation that abolishes hydrogen bonds in the capsid structure, leading to a loss of compound binding. Structure-based analysis has defined the amino acids responsible for the inhibitor's inefficacy against other DENV serotypes. The results have uncovered an antiviral mechanism through inhibitor-induced tetramerization of the viral capsid and provided essential structural and functional knowledge for rational design of panserotype DENV capsid inhibitors.
登革热病毒(DENV)在 2019 年被世界卫生组织列为全球 10 大公共卫生威胁之一。目前尚无临床批准的抗 DENV 药物。本研究报道了 DENV-2 衣壳蛋白与一种强效抑制 DENV-2 但不抑制其他 DENV 血清型的抑制剂的高分辨率共晶结构(1.5Å)。抑制剂诱导两个衣壳二聚体之间的“亲吻”相互作用。结合抑制剂的衣壳四聚体在病毒粒子内组装,导致感染新细胞时核衣壳脱壳缺陷。通过一个突变产生耐药性 DENV-2,该突变破坏了衣壳结构中的氢键,导致化合物结合丧失。基于结构的分析定义了负责抑制剂对其他 DENV 血清型无效的氨基酸。这些结果揭示了通过抑制剂诱导病毒衣壳四聚化的抗病毒机制,并为设计泛血清型 DENV 衣壳抑制剂提供了重要的结构和功能知识。